文献速递泌尿生殖与妇科肿瘤放疗

单次高剂量率近距离治疗中危前列腺癌的复发模式与结局

Patterns of relapse and outcomes following Single-Fraction High-Dose-Rate brachytherapy monotherapy for Intermediate-Risk prostate cancer.
PubMed 文献 · Radiother Oncol · 2025-10-20

本研究回顾性分析了87例接受单次21 Gy高剂量率近距离治疗(HDRB)单药治疗的中危前列腺癌(IRPC)患者,中位随访51.1个月。5年生化无复发生存率(bRFS)在有利中危组为83.4%,不利中危组为59.3%;急性≥3级泌尿生殖毒性为5.7%,晚期≥3级毒性为1.1%。复发模式与剂量学覆盖不足无关,基线PSA较高和不利中危分类与局部复发风险增加相关。

要点

  • 单次21 Gy HDRB单药治疗IRPC可行且安全,5年OS达96.6%。
  • 5年bRFS在有利中危组为83.4%,不利中危组为59.3%。
  • 基线PSA较高和不利中危分类与局部复发风险增加独立相关。

核心结论

  • 单次21 Gy HDRB单药治疗中危前列腺癌可行且安全,有利中危组5年bRFS为83.4%,不利中危组为59.3%。
  • 复发模式不能归因于剂量学覆盖不足,基线PSA较高和不利中危分类与局部失败风险增加相关。

研究设计与样本

  • 从病历中提取临床数据、治疗参数和结局,由盲法泌尿生殖放射科医生诊断的放射学局部复发经活检确认。
  • 对复发的前列腺内结节进行剂量学分析,毒性采用CTCAE v4分级。

主要发现

  • 生化失败发生于24.1%的患者,其中局部复发占16.1%。
  • 5年bRFS在有利中危组为83.4%,不利中危组为59.3%;5年LRRFS分别为82.6%和76.9%;5年OS为96.6%。
  • Cox模型显示基线PSA较高(HR 1.2,95%CI 1.0-1.42,p=0.013)和不利中危分类(HR 4.52,95%CI 1.4-14.1,p=0.01)与局部复发风险增加相关。
  • 接受100%处方剂量的前列腺体积较大具有保护作用(HR 0.85,95%CI 0.75-0.96)。
  • 复发灶剂量学分析(D98%=21.6 Gy,D90%=23.7 Gy,Dmean=30.6 Gy)显示与失败无关联。

关键数值与推荐

  • 急性≥3级泌尿生殖毒性发生率为5.7%,晚期≥3级毒性为1.1%。
  • 未观察到≥2级胃肠道毒性。
  • 复发灶剂量学参数:D98%=21.6 Gy,D90%=23.7 Gy,Dmean=30.6 Gy。

临床怎么用

  • 单次21 Gy HDRB单药治疗可作为中危前列腺癌的一种可行选择,尤其适用于有利中危患者。
  • 对基线PSA较高或不利中危分类的患者,应加强局部复发监测。
  • 治疗计划中应关注接受100%处方剂量的前列腺体积,以降低局部失败风险。

局限性

  • 回顾性研究设计,样本量87例,中位随访51.1个月。
  • 复发灶剂量学分析样本量有限,未显示与失败的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: High-dose rate brachytherapy (HDRB) monotherapy has proven effective in managing low- and intermediate-risk prostate cancer (IRPC). This study aims to evaluate patterns of relapse, treatment-related toxicity, and tumor control in patients with IRPC treated with a single fraction of HDRB monotherapy. METHODOLOGY: We reviewed IRPC patients treated with HDRB monotherapy delivered as a single 21 Gy fraction between January 2015 and December 2021. Clinical data, treatment parameters, and outcomes were extracted from medical records. Radiological local recurrences diagnosed by a blinded genitourinary radiologist were confirmed by biopsy. We performed dosimetric analysis of recurrent intraprostatic nodules. Toxicities were graded using CTCAE v4. We report 3- and 5-year biochemical relapse-free survival (bRFS), locoregional relapse-free survival (LRRFS), and overall survival (OS). RESULTS: 87 patients were included (median follow-up: 51.1 months). Biochemical failure occurred in 24.1 % of patients, including local relapse in 16.1 %. Using Cox proportional-hazards model, higher baseline PSA and unfavorable intermediate-risk (UIR) category were associated with an increased local relapse risk (HR 1.2 [95 % CI 1.0-1.42], p = 0.013; HR 4.52 [95 % CI 1.4-14.1], p = 0.01, respectively), whereas a greater prostatic volume receiving 100 % of the prescription dose was protective (HR 0.85 [95 % CI 0.75-0.96]). Dosimetric analyses of recurrences (D98% = 21.6 Gy, D90% = 23.7 Gy, Dmean = 30.6 Gy) showed no association with failure. The 5-year bRFS rate for favorable intermediate-risk (FIR) patients was 83.4 %, and for UIR patients 59.3 %. The 5-year LRRFS rate was 82.6 % for FIR and 76.9 % for UIR patients. The 5-year OS was 96.6 %. Acute grade ≥ 3 genitourinary toxicities occurred in 5.7 % of patients, and late grade ≥ 3 toxicity in 1.1 %. No grade ≥ 2 gastrointestinal toxicity was observed. CONCLUSION: A single 21 Gy fraction of HDR brachytherapy monotherapy for IRPC appears feasible and safe, yielding a 5-year bRFS of 83.4 % for FIR and 59.3 % for UIR patients. Patterns of failure were not attributable to inadequate dosimetric coverage. Higher baseline PSA levels and UIR classification were associated with an increased risk of local failure.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Martinez C, Paragas J, Alvarado L, et al. Patterns of relapse and outcomes following Single-Fraction High-Dose-Rate brachytherapy monotherapy for Intermediate-Risk prostate cancer. Radiother Oncol. 2025. PMID: 41115596. doi:10.1016/j.radonc.2025.111211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。